

KFIN/CERT13(3)/MAR/2023
April 7, 2023

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli
Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31, 2023.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2023.

Description of Complaint	Opening Balance as on 01.01.2023	Received during the Period 01.01.2023 to 31.03.2023	Attended/Resolved during the Period 01.01.2023 to 31.03.2023	Pending as on 31.03.2023
Non-receipt of Dividend	NIL	09	09	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	07	07	NIL
SEBI	NIL	07	07	NIL
Stock Exchange	NIL	NIL	NIL	NIL
Total	NIL	23	23	NIL

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Limited



Rajitha Cholleti
Dy. Vice President